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 3 
Abstract 
Hearing loss is the fastest growing and one of the most prevalent chronic health 
conditions in the world. Cisplatin, a drug widely used in the treatment of many cancers, 
has been shown to be particularly damaging to the inner ear, causing ototoxicity in 70-
100% of patients treated. Previous studies demonstrated the accumulation of reactive 
oxygen species (ROS) in hair cells as a major contributor to hair cell death in response 
to ototoxic drugs, noise exposure, and age-related hearing loss. The antioxidant 
enzyme catalase, predominantly localized in the peroxisome of cells, plays a crucial role 
in regulating cellular oxidative stress by degrading ROS. In the present study, we 
investigated whether our novel antioxidant CAT-SKL – a stable, cell penetrating, 
peroxisome-targeted derivative of catalase – is able to offer protection against cisplatin-
induced ototoxicity in the HEI-OC1 immortalized mouse cochlear cell line. Using 
immunocytochemistry and western blot techniques, we confirmed that CAT-SKL was 
successfully internalized when delivered to cells in vitro. A WST-1 cell viability assay 
demonstrated that CAT-SKL is not only non-toxic to cells derived from the inner ear, but 
significantly improved cell viability compared to untreated cells in a dose-dependent 
manner. As expected, 15µM cisplatin treatment induced a significant decrease in cell 
viability of HEI-OC1 cells. This decrease was ameliorated by pretreatment with 10µM 
CAT-SKL. Furthermore, even at a cisplatin concentration of 30µM, pretreatment with 
CAT-SKL was still able to improve cell viability. In addition, cisplatin treatment resulted 
in increased levels of ROS as detected by dihydroethidium staining and induced 
peroxisomal proliferation. Pretreatment with 10µM CAT-SKL was able to attenuate 
cisplatin-induced damage due to its antioxidant properties, thereby decreasing ROS 
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formation and peroxisomal proliferation. At present, there is no widely accepted 
pharmacotherapy which protects against ototoxic pharmaceuticals. The results of this 
project demonstrate a safe and effective prophylactic intervention for protection against 
ototoxic drug-induced hearing loss.  
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Introduction 
Hearing loss is the fastest growing and one of the most prevalent chronic health 
conditions in the world1. According to the WHO, it affects approximately 360 million 
people, which is over 5% of the world’s population2. The consequences of hearing loss 
and tinnitus, the perception of a ringing sound in the ears that often accompanies 
hearing loss, are extensive3. It has tremendous implications on an individual’s ability to 
communicate effectively, which can seriously impact patients in their professional and 
personal lives, leading to isolation, withdrawal, and exacerbation of other psychological 
disorders4. There is also clear evidence linking hearing loss to an increased risk of 
developing dementia, Alzheimer’s disease, and the acceleration of age-related cognitive 
decline5. Given the prevalence and widespread consequences of hearing loss, there is 
a crucial need to develop novel compounds that can be administered prophylactically to 
limit permanent damage to the auditory system.  
Causes of Hearing Loss  
Some common causes of hearing loss and tinnitus include exposure to loud 
noise6; ototoxic drugs such as the aminoglycoside antibiotics (e.g. kanamycin, 
gentamicin, and neomycin7) and platinum-based chemotherapeutic agents (e.g. 
cisplatin, oxaliplatin, and carboplatin8,9). Aminoglycoside induced hearing-loss occurs in 
approximately 20% of patients undergoing short-term treatments10. In comparison, 
cisplatin therapy is associated with a higher occurrence of hearing deficits10. According 
to Rybak et al., the incidence of cisplatin-mediated ototoxicity is estimated to occur in 
approximately 75-100% of patients treated with the medication9.  
Despite the ototoxicity of these platinum-based chemotherapeutic agents and 
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aminoglycosides, these drugs still remain in use. This occurs either because the risk of 
damage is relatively small, or because no comparative alternative treatment options are 
available10. In particular, there is a large demand for aminoglycoside antibiotics in 
developing nations due to their broad-spectrum efficacy against most infections and low 
cost of production10.  
Cisplatin is widely used as a chemotherapeutic agent, either singly or in 
combination therapy11. It is used in the treatment of head, neck, lung, bladder, cervical, 
and gastrointestinal cancers11. More recently, other platinum-based chemotherapeutic 
agents, such as carboplatin and oxaliplatin, have been developed. However, they are 
used in very limited applications: carboplatin is used in the treatment of specific types of 
breast cancers and oxaliplatin is used in combination therapy against colorectal 
cancer10. Although cisplatin is the most ototoxic in the family of platinum-based 
chemotherapeutic drugs, it is still used far more often than others because it is 
approximately 40 times more effective against certain cancers compared to carboplatin 
or oxaliplatin10.  
Mechanism of Cisplatin-Induced Ototoxicity  
Cisplatin or aminoglycoside induced hearing loss is generally bilateral and begins 
in the higher frequency region of the inner ear12. With prolonged treatment, this damage 
will extend to the lower frequencies12. Furthermore, aminoglycosides can also elicit 
vestibulotoxicity which manifests as a loss of balance with or without vertigo10. Both 
cisplatin and aminoglycosides cause nephrotoxicity by accumulating in the kidneys10. 
Previous studies using multiple cell systems, including an immortalized cochlear cell 
line, have identified the mammalian copper transporter 1 (CTR1) as the major influx 
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transporter of platinum-based drugs, such as cisplatin, and the glycoprotein transporter 
megalin in the case of aminoglycosides8,10. Although these drugs are both nephrotoxic 
and ototoxic, the renal toxicity is reversible, while any damage to the inner ear is usually 
permanent9. Studies have shown that in hair cells, cisplatin acts to generate a 
substantial amount of reactive oxygen species (ROS) while depleting endogenous 
antioxidant enzymes that would normally be able to neutralize this increase11. Moreover, 
cisplatin tends to accumulate in cochlear tissues and integrates itself into the DNA, 
causing inefficient and dysfunctional protein and enzyme synthesis11. Previous studies 
by Ding et al., showed that high levels of extracellular cisplatin do not induce hair cell 
loss or stereocilia damage8. It is instead the intracellular accumulation of cisplatin that 
results in its ototoxic effects. Because of the cochlea’s unique anatomical position and 
isolation, it resembles a closed system, and its ability to remove these accumulated 
toxins, such as cisplatin, is very limited. This leads to ROS overload, and when 
combined with an inefficient antioxidant system, apoptosis will occur10. Research has 
shown the down-regulation of cochlear antioxidant enzymes such as catalase, 
superoxide dismutase (SOD), glutathione peroxidase, and glutathione reductase 
increases the vulnerability of the cochlea to damage associated with normal aging13.  
The Role of Reactive Oxygen Species in Hearing Loss  
Reactive oxygen species are typically formed as a byproduct during the normal 
cellular metabolism of oxygen14. However, during times of environmental stress, ROS 
levels can increase and damage cells by interacting with DNA, RNA and other cellular 
components14,15. Numerous studies have shown that oxidative stress is a key factor in 
the pathophysiology of noise trauma. For example, in noise-exposed animals, a 
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significant increase in oxidative stress markers was observed in the cochlea16. Many 
studies have attempted to offset this oxidative stress by administering dietary 
antioxidants to noise-exposed animals, with limited effectiveness17. Moreover, 
administration of dietary antioxidants that appeared to lessen noise-induced hearing 
loss in preclinical models were unable to provide equally promising results when 
administered to humans18.  
The Role of Catalase in Hearing loss  
Normally found in the peroxisomes of cells, the endogenous antioxidant, 
catalase, plays an integral role in protecting cochlear hair cells from oxidative stress19. 
Catalase catalyzes the degradation of hydrogen peroxide to water and oxygen (2H2O2 -
> 2H2O + O2), thus preventing the oxidative damage in the cell caused by hydrogen 
peroxide20. The enzyme is a tetramer with a total molecular weight of 240kDa, and each 
tetrameric molecule contains four heme groups21. Studies involving both rodents and 
humans have confirmed that it would be highly desirable to therapeutically increase, or 
at least preserve, catalase following noise exposure. For example, transgenic mice that 
overexpress catalase were resistant to age-related hair cell death and hearing loss15. 
Furthermore, research on animal models has shown that in the days following noise 
exposure, catalase levels decrease22,23. Finally, human polymorphisms in the catalase 
encoding gene have been linked to an increased vulnerability to noise-induced hearing 
loss19. These studies suggest that compounds that augment or preserve the catalase 
system in the cochlea may be protective against noise-induced hearing loss.  
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The Creation of a Recombinant Derivative of Catalase 
Similar to dietary antioxidants, flooding the body with supplemental catalase is 
not an effective option because it needs to effectively penetrate the cells undergoing 
oxidative stress, and then enter their peroxisomes. As a first step towards overcoming 
this obstacle, Dr. Paul Walton has succeeded in engineering a recombinant derivative of 
catalase (Patent No. US20060141598 A1)24. Normally, the catalase protein contains a 
KANL sequence at the carboxyl terminus. Although KANL functions as a peroxisome 
targeting sequence, its targeting efficiency is limited. It was found that other proteins 
that were more effectively targeted to the peroxisomes contained a more efficient motif 
(SKL) at its carboxyl terminus. Thus, in the recombinant derivative of catalase, the 
KANL sequence of catalase was replaced with the SKL sequence to form Catalase-SKL 
(CAT-SKL). Upon its administration, CAT-SKL can penetrate cells via a cell penetrating 
peptide (CPP) at its amino terminus. The CPP is an arginine-rich region that enhances 
the uptake of the modified catalase into cells. Previous studies conducted by Giordano 
et. al. demonstrated the efficacy of CAT-SKL in reducing Amyloid-beta (Aβ)-induced 
neurotoxicity, which is a major contributor to the pathologies associated with 
Alzheimer’s disease25. CAT-SKL administration was able attenuate ROS formation, 
neurite formation and restore overall cell viability. In addition, CAT-SKL has also been 
shown to be efficacious in reducing ischemia reperfusion injury induced cell death, 
which occurs due to generation of oxidative stress in ventricular myocytes26.  
The HEI-OC1 Cell Line  
Thus, the aim of this project was to design a high-throughput system for testing 
the otoprotective effects of CAT-SKL. To further investigate the cellular mechanisms 
 10 
involved in CAT-SKL protection against ototoxic agents, the house ear institute-organ of 
corti 1 (HEI-OC1) cell line was used27. This cell line, derived from the auditory organ of 
the transgenic ImmortomouseTM, expresses specific markers of cochlear hair cells such 
as prestin and myosin 7a27. Studies have provided substantial evidence that typical 
ototoxic drugs such as cisplatin, kanamycin, and gentamicin-induced caspase-3 
activation in these cells, while non-ototoxic drugs such as penicillin did not27. Therefore, 
this cell line has been used widely as an in vitro system to investigate the molecular 
mechanisms involved in ototoxic compounds or otoprotective properties of new 
pharmacological drugs.  
Because HEI-OC1 cells are vulnerable to damage by ototoxic agents, I 
hypothesized that cisplatin would decrease the viability of HEI-OC1 cells. 
Additionally, I hypothesized that addition of CAT-SKL would protect against the 
reduced viability of HEI-OC1 cells caused by exposure to cisplatin.  
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Materials and Methods  
HEI-OC1 Cell line  
The House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line, derived from the cochlea 
of the Immorto-mouseTM, was provided by Dr. F. Kalinec27. The cells were maintained in 
high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 
10% fetal bovine serum (FBS; Gibco) at 33oC in a humidified incubator with 5% CO2. 
HEI-OC1 cells were passaged using 0.25% trypsin with EDTA (Gibco).  
Drug treatments  
Cisplatin (Sigma-Aldrich; 15663-27-1) and Catalase-SKL (made by Dr. Paul Walton; 
stock concentration at 32 mg/mL dissolved in sterile PBS) were added to their 
respective culture mediums at assay specific concentrations, followed by incubation at 
33oC for assay specific time periods. Menadione (Sigma-Aldrich; M5625), a known 
inducer of cellular oxidative stress, was dissolved in 100% ethanol at a stock 
concentration of 50mM. It was used as a positive control for oxidative stress at a 
concentration of 100μM dissolved in media.  
Detection of cell viability   
HEI-OC-1 cells were counted and seeded at density of 1x104 cells in medium onto a 96-
well plate and incubated overnight for attachment. Each well contained a volume of 
100μL. Cells were then treated with CAT-SKL (1μM, 2.5μM, 5μM or 10μM) for a 24-hour 
pretreatment period followed by 48 hours of cisplatin (15μM, 20μM or 30μM) exposure. 
Cell proliferation reagent WST-1 (Sigma-Aldrich; 5015944001) was then added to each 
well at a ratio of 1:10 (10μL of WST-1 per well). After 1.5 h of incubation, cell viability 
was determined by measuring the absorbance at 450 nm using a BioTek Epoch 
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Microplate Spectrophotometer. Each assay was performed in triplicate, with six 
replicates run on each plate.  
Immunohistochemistry for detection of Catalase-SKL internalization, reactive 
oxygen species, and peroxisomal proliferation 
HEI-OC1 cells were plated on circular coverslips with 2 coverslips placed in each well 
of a 6-well plate. Each well was seeded with 8x104 cells in fresh medium. After 24 h 
incubation, coverslips were treated with CAT-SKL (1μM, 2.5μM, 5μM or 10μM) for a 
24-hour pretreatment period followed by 48 hours of cisplatin (15μM, 20μM or 30μM) 
exposure. Cells were then washed for 5 min twice with PBS and fixed with 4% 
paraformaldehyde in PBS for 30 min at room temperature. The solution was aspirated 
and coverslips were placed into a humidity chamber and washed twice for 5 min with 
PBS. A permeabilization solution comprised of 0.5% Triton X-100 solution in PBS 
was added the coverslips for 30 min. The coverslips were washed again for 5 min 
three times with PBS. Finally, a blocking solution comprised of 3% bovine serum 
albumin (BSA) and 0.1% Triton X-100 in PBS was added to each coverslip. Coverslips 
were incubated with the blocking solution for 1 h at room temperature.  
To track CAT-SKL internalization, a biotinylated form of CAT-SKL (bCAT-SKL) was 
used. Alexa FluorTM streptavidin 488 (Thermo Scientific; S11223) at a dilution of 1:400 
in the blocking buffer at room temperature for 1 h was used to detect the presence of 
bCAT-SKL. Coverslips were then washed three times for 5 min each with PBS. Then, 
coverslips were mounted with ProLong Diamond Antifade Mountant with 4′,6-
diamidino-2-phenylindole (Thermo Scientific; P36962) onto glass slides.  
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To visualize peroxisomes, after incubation with blocking solution, coverslips were 
incubated with the primary antibody, rabbit polyclonal anti-PMP70 (70kDa-peroxisomal 
membrane protein; Affinity BioReagents; PA1-650), at a dilution of 1:200 in the 
blocking buffer at 4oC overnight. Coverslips were then washed three times for 5 min 
each with PBS, then incubated for 1 h at room temperature with secondary antibody, 
Alexa FluorTM 594 donkey anti-rabbit IgG (Thermo Scientific; A-11008). Coverslips were 
washed again at 5 mins each with PBS for three times. Coverslips were mounted with 
ProLong Diamond Antifade Mountant with 4′,6-diamidino-2-phenylindole (Thermo 
Scientific; P36962) onto glass slides.  
Cells were imaged with a Zeiss LSM 800 confocal Airyscan microscope equipped with 
ZenWorks software. Images were captured with a ×63 oil immersion objective at room 
temperature.  
To detect reactive oxygen species, dihydroethidium (DHE) stain (Thermo Scientific; 
D1168) was used. The media was aspirated and coverslips were rinsed 3 times in 
PBS for 5 min. The coverslips were incubated with 10μM of DHE for 30 min, covered 
in the dark. Finally, the coverslips were rinsed three times with PBS for 5 min each. A 
small drop of PBS was placed on a glass slide and one at a time, coverslips were 
mounted onto the glass slide and sealed with clear nail polish. The slides were then 
immediately visualized and imaged with a Zeiss LSM 800 confocal Airyscan microscope 
equipped with ZenWorks software. Images were captured with a ×63 oil immersion 
objective at room temperature. 
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Western blot 
HEI-OC1 cells were plated at a density of 8x105 cells per well of a 6-well plate. After 
24 h incubation, cells were treated with CAT-SKL for 24 hours. Media was then 
aspirated and cells were twice with cold PBS. 1x lysis buffer was made containing 2x 
immunoprecipitation buffer, sodium orthovanidate (100mM), sodium fluoride (100mM), 
cOmplete™Mini EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich; 11836170001) 
dissolved in ddH2O. Lysis buffer was added to the cells and cell lysates were scraped 
using a rubber policeman. Solutions were transferred to 1.5mL tubes and placed on ice 
for 30 min, vortexing periodically. Solutions were then centrifuged at 4oC for 15 min at 
12,000RPM. Supernatant was transferred to newly labeled 1.5mL tubes. Protein 
concentration was determined using a bicinchoninic acid (BCA) assay (Thermo 
Scientific; 23225) in a 96 well plate. After determining the concentration, 30μg of 
protein/lane was separated by electrophoresis on 12% SDS-PAGE gels and transferred 
to nitrocellulose membranes for immunoblotting. The nitrocellulose membrane was 
blocked with 3% BSA solution for 1 h and then incubated overnight at 4oC with rabbit 
polyclonal anti-catalase (1:200; Thermo Scientific; PA5-29183) antibody and mouse 
monoclonal anti-GAPDH (1:7500; Milipore, Billerica, MA). Primary antibodies were 
detected using goat anti-rabbit IRdye 800 (1:10,000; LI-COR Biosciences) and Alexa 
Fluor 680 goat anti-mouse (1:10,000; Invitrogen) secondary antibodies. Membranes 
were scanned and quantified using the Odyssey Infrared Imaging System (LI-COR 
Biosciences).  
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Statistical analysis  
GraphPad Prism version 6 was used for all statistical analysis. All data are presented as 
mean ± SEM. When a One-way ANOVA for non-repeated measures was performed, 
the Dunnett’s post hoc test was used to compared between treatments and control. 
When a Two-way ANOVA for non-repeated measures was performed. Tukey’s post hoc 
test was used for multiple comparisons. Data was determined to be statistically 
significant when p<0.05. 
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Results  
CAT-SKL is successfully internalized in HEI-OC1 cells  
Internalization of the CAT-SKL was documented in HEI-OC1 cells, with entry confirmed 
within 24 hours of addition. To demonstrate CAT-SKL internalization in HEI-OC1 cells, 
CAT-SKL was tracked using a biotinylated form of the recombinant enzyme (Fig. 1a). 
Immunofluorescence analysis confirmed catalase staining was noticeably increased in 
CAT-SKL treated cells relative to untreated cells. To confirm that treatment of HEI-OC1 
cells with 10µM of CAT-SKL did indeed lead to an increase in the intracellular level of 
the exogenous catalase protein, a western blot was performed (Fig. 1b). Endogenous 
expression levels of the catalase protein (60kDa) are comparable between the 
untreated group and the CAT-SKL treated group with both showing a band of relatively 
equal intensity at 60kDa. However, the cells of the CAT-SKL treated group showed an 
additional band at 65kDa when probed with an anti-catalase antibody. This signifies the 
successful internalization of exogenous CAT-SKL, which has a slightly higher molecular 
weight due to the additional cell penetrating peptide on the recombinant protein. 
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Figure 1. CAT-SKL uptake in HEI-OC1 cells. A) Immunocytochemistry showed HEI-
OC1 cells stained for 4′,6-diamidino-2-phenylindole (DAPI) (blue) and streptavidin 
(green). Cells incubated with 10µM CAT-SKL for 24 hours showed a noticeable 
increase in streptavidin staining compared to untreated cells (Bars, 10µM). B) Western 
blot was also performed to confirm the internalization of CAT-SKL in HEI-OC1 cells. 
Cells were either incubated with CAT-SKL (10µM) for 24 hours or untreated. The 
membrane was probed with anti-catalase antibody (1:200). GAPDH (1:7500) was used 
as a loading control. Results are shown from the same probed blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
CAT-SKL is not harmful to HEI-OC1 cells  
To confirm CAT-SKL is not harmful to HEI-OC1 cells, a WST-1 cell proliferation assay 
was performed. HEI-OC1 cells were incubated with 1µM, 2.5µM, 5µM, or 10µM of CAT-
SKL for 24 hours. The cell viability of each group was obtained by measuring the 
absorbance at 450nm using a spectrophotometer. The background absorbance was 
measured for a blank well filled with media only and this value was subtracted from all 
samples. To compare cell viability between CAT-SKL treated cells and control cells, a 
one-way non-repeated measure ANOVA was performed. When ANOVA indicated 
significant treatment effects (p<0.05), means were separated using Dunnett’s multiple 
comparison’s test, comparing all groups to the untreated control group. The ANOVA 
revealed a significant main effect for treatment (F(5,102)=89.73 , p<0.0001). The results of 
post-hoc testing revealed that the addition of CAT-SKL at 1µM or 2.5µM does not 
significantly alter cell viability compared to untreated cells (p>0.05). However, at higher 
concentrations of CAT-SKL (5µM and 10µM), there is a significant increase in cell 
viability compared to untreated cells (p<0.0001). Menadione, a known cellular oxidative 
stressor, was used as a positive control. As expected, the addition of menadione at 
100µM for 1h caused a significant reduction in cell viability (p<0.0001).  
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Figure 2. CAT-SKL is not harmful to HEI-OC1 cells. HEI-OC1 cells were incubated 
with CAT-SKL for 24 hours prior to assessment of cell viability using the WST-1 cell 
proliferation assay.  Menadione, a known oxidative stress inducing reagent was used as 
a positive control. Addition of menadione (100µm) for 1 hour induced a significant 
decrease in cell viability. Incubation with CAT-SKL at 1µM and 2.5µM for 24 hours did 
not result in a significant deviation from the control. However, addition of CAT-SKL at 
5µM and 10µM significantly increased cell viability. Statistical analysis was performed 
using a one-way ANOVA, non-repeated measures. When ANOVA indicated significant 
treatment effects (p<0.05), means were separated using Dunnett’s multiple 
comparison’s test, comparing all groups to the untreated control group. Bars represent 
mean ± SEM for triplicate samples (N=3, n=18).  
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CAT-SKL protects against cisplatin-induced ototoxicity  
Next, we examined the protective effects of CAT-SKL against cisplatin-induced toxicity 
in HEI-OC1 cells. To accomplish this, WST-1 cell proliferation reagent was used. HEI-
OC1 cells were pretreated with either 1µM, 2.5µM, 5µM, or 10µM of CAT-SKL for 24 
hours and subsequently challenged with 15µM of cisplatin, which has been previously 
reported as the IC50 of cisplatin, for 48 hours. To compare the cell viability between 
CAT-SKL pretreated cells, control cells and cisplatin only cells, a one-way non-repeated 
measure ANOVA was performed. When ANOVA indicated significant treatment effects 
(p<0.05), means were separated using Dunnett’s multiple comparison’s test, comparing 
all groups to the cisplatin only (15µM) group. The ANOVA revealed a significant main 
effect for treatment (F(5,103)=10.52, P<0.0001). As expected, cells treated with cisplatin 
alone had a significant reduction in cell viability compared to untreated cells (Fig. 2b; 
p<0.01). CAT-SKL was protective against cisplatin exposure in a dose dependent 
manner. Pretreatment with CAT-SKL at 1µM and 2.5µM did not demonstrate a 
protective effect against cisplatin exposure as there were no significant differences in 
percent cell viability as compared to cells treated with cisplatin only (p>0.05). 
Pretreatment with CAT-SKL at 5µM and 10µM exhibited a protective effect against 
cisplatin exposure as evidenced by a significant increase in cell viability compared to 
cells treated with cisplatin alone (p<0.01). 
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Figure 3. CAT-SKL is protective against cisplatin-induced ototoxicity.  HEI-OC1 
cells were incubated with CAT-SKL for 24 hours before assessment of cell viability 
using the WST-1 cell proliferation assay.  Incubation with cisplatin at 15µM showed a 
significantly reduced percent cell viability compared to untreated cells. Pretreatment 
with CAT-SKL at 1µM and 2.5µM followed by cisplatin challenge did not significantly 
improve percent cell viability. However, pretreatment with CAT-SKL at 5µM and 10µM, 
followed by cisplatin challenge, did significantly increase the percent cell viability 
compared to the cells exposed to cisplatin only. Statistical analysis was performed using 
a one-way ANOVA, non-repeated measures. When ANOVA indicated significant 
treatment effects (p < 0.05), means were separated using Dunnett’s multiple 
comparison’s test and comparing all groups to the cisplatin treated group. Bars 
represent mean ± SEM for triplicate samples (N=3, n=18).  
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CAT-SKL improves cell viability even at high concentrations of cisplatin  
Having established the protective effect of CAT-SKL in our cisplatin-induced HEI-OC1 
ototoxicity model, we next sought to investigate whether CAT-SKL was able to offer 
sufficient protection against higher doses of cisplatin. To accomplish this, WST-1 cell 
proliferation reagent was used. Cell viability was determined in HEI-OC1 cells 
pretreated with 10µM of CAT-SKL for 24 hours and subsequently challenged with 
15µM, 20µM, and 30µM of cisplatin for 48 hours (Fig. 4). A two-way ANOVA revealed a 
significant main effect for CAT-SKL treatment (F(1,135)=153.3, p<0.0001), a significant 
main effect for cisplatin treatment (F(3,135)=80.75, p<0.0001), as well as a significant 
interaction between CAT-SKL and cisplatin treatments (F(3,135)=4.115, p<0.01). As 
expected, Tukey’s post hoc test showed increasing the concentration of cisplatin (15µM, 
20µM, and 30µM) resulted in significantly greater reductions in cell viability relative to 
untreated cells (p<0.0001). Additionally, it was observed that pretreatment with CAT-
SKL (10µM) increased the cell viability after challenge by cisplatin such that cells 
pretreated with CAT-SKL, then treated with cisplatin at both 15µM, 20µM, no longer 
exhibit significant differences in cell viability compared to untreated cells (p>0.05). 
Moreover, at all three concentrations of cisplatin (15µM, 20µM, and 30µM), 
pretreatment with CAT-SKL then challenge by cisplatin, significantly improved the cell 
viability compared to cisplatin only cells (p<0.0001). Surprisingly, pretreatment with 
CAT-SKL was able to improve cell viability even at the highest dose of cisplatin that was 
tested (30µM).  
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Figure 4. CAT-SKL is able to improve cell viability even at high concentrations of 
cisplatin. HEI-OC1 cells were incubated with CAT-SKL for 24 hours before assessment 
of cell viability using the WST-1 cell proliferation assay.  Incubation with cisplatin at 
15µM, 20µM, or 30µM showed a significant reduction in percent cell viability compared 
to untreated cells in a dose dependent manner. Pretreatment with CAT-SKL at 10µM 
followed by cisplatin challenge for 48 hours at all three concentrations significantly 
improved the percent cell viability. Most noticeably, pretreatment with CAT-SKL at 10µM 
was able to improve the decrease in percent cell viability caused by 30µm of cisplatin. 
Two-way ANOVA was performed, means were separated using Tukey’s post hoc test. 
(*) represent significant differences within cisplatin treatment groups; (‡) represent 
significant differences from untreated cells. Bars represent mean ± SEM for triplicate 
samples (N=3, n=18).   
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CAT-SKL ameliorates cisplatin-induced production of reactive oxygen species  
Using dihydroethidium staining, we examined the protective effects of CAT-SKL against 
cisplatin-induced production of reactive oxygen species in HEI-OC1 cells. HEI-OC1 
cells were either left untreated, treated with 10µM of CAT-SKL alone, treated with 30µM 
of cisplatin alone, or pretreated with 10µM of CAT-SKL prior to exposure to 30µM of 
cisplatin. As predicted, treatment with 30µM of cisplatin caused a noticeable increase in 
red fluorescence, signifying high levels of superoxide radicals within the cells. 
Pretreatment with CAT-SKL decreased the cisplatin-induced increase in superoxide 
radicals, as evidenced by a decrease in red fluorescence. Incubation with CAT-SK 
alone did not cause a noticeable change in the levels of reactive oxygen species 
compared to the untreated cells.  
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Figure 5. CAT-SKL restores oxidative equilibrium to cisplatin challenged cells. 
HEI-OC1 cells were incubated with CAT-SKL for 24 hours before assessment of cellular 
superoxide radical content using a dihydroethidium (DHE) staining (red). Incubation with 
cisplatin (30µM) showed noticeably higher levels of red fluorescence. Pretreatment with 
CAT-SKL (10µM), followed by cisplatin challenge was able to attenuate the ROS 
content. Similar levels of red fluorescence were observed between untreated and CAT-
SKL (10µM) group, suggesting CAT-SKL administration does not result in increased 
ROS production (scale bars, 10µm).  
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CAT-SKL attenuates cisplatin-induced peroxisomal proliferation  
Previous studies have reported proliferation of peroxisomes in cells undergoing either 
the aging process or diseased states28,29. This proliferation has been postulated to 
compensate for the compromised peroxisome function and further assist the 
mitochondria in metabolizing the overwhelming formation of ROS24. To detect 
peroxisomal proliferation, immunocytochemistry was performed on HEI-OC1 cells. Cells 
were stained for DAPI (DNA stain) and anti-PMP70 (70kDa-Peroxisomal membrane 
protein), a common peroxisome marker. HEI-OC1 cells were pretreated with CAT-SKL 
(10µM) for 24 hours prior to exposure to either 15µM or 30µM cisplatin for 48 hours. 
CAT-SKL only and untreated cells were also stained as control groups. In both control 
and CAT-SKL only groups, no noticeable difference in peroxisomal staining or 
distribution was observed. As predicted, cells treated with either 15µM or 30µM of 
cisplatin alone exhibited increased amounts of anti-PMP70 staining in both the cell body 
and cell processes, signifying peroxisomal proliferation. Pretreatment with CAT-SKL 
(10µM) followed by cisplatin challenge (15µM or 30µM) showed noticeable attenuation 
peroxisomal proliferation and resulted in peroxisomal staining more akin to that seen in 
untreated cells.  
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Figure 6. CAT-SKL attenuates cisplatin-induced peroxisomal proliferation.  
Immunocytochemistry was performed on HEI-OC1 cells stained for DAPI (blue) and 
anti-PMP70 (red). HEI-OC1 cells challenged with cisplatin (15µM and 30µM) exhibited a 
greater expression of the peroxisomal marker PMP70.  Pretreatment with CAT-SKL 
diminished these changes, resulting in peroxisomal staining and distribution more 
comparable to that seen in untreated cells (scale bars, 10µm).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
Discussion  
In this study, we investigated the protective effects of the targeted antioxidant, 
catalase-SKL, on cisplatin-induced ototoxicity in HEI-OC1 cells. We demonstrated that 
administration of CAT-SKL is not only innocuous to HEI-OC1 cells, but will also 
significantly improve cell viability at high concentrations. In addition, treatment of HEI-
OC1 cells with the ototoxic compound, cisplatin, resulted in decreased cell viability, 
increased levels of reactive oxygen species, and induced peroxisomal proliferation. 
Pretreatment with CAT-SKL (10µM) was able to attenuate cisplatin-induced damage 
due to its antioxidant properties. By decreasing ROS levels, the toxicity induced by 
cisplatin was lessened thereby increasing cell viability, decreasing ROS formation, and 
decreasing the proliferation of peroxisomes.  
The results of this study add to a growing body of literature demonstrating the 
effectiveness of CAT-SKL as a targeted antioxidant to reduce cellular stress caused by 
ROS. Previous studies explored the efficacy of CAT-SKL in reducing cell death caused 
by amyloid β-derived diffusible ligands (ADDL)25. ADDLs have commonly been used 
to stimulate accumulation of Aβ-formation, which is a major precursor in Alzheimer’s 
disease25. Their research demonstrated that CAT-SKL administration was able to 
protect against ADDL-induced cytotoxicity in rat primary cortical and hippocampal 
cultures25. Namely, CAT-SKL improves overall cell viability, stimulates neurite 
formation and reduces ROS production25. Furthermore, the antioxidant capabilities of 
CAT-SKL have also been demonstrated on a model of ischemia-reperfusion injury 
(IRI) in neonatal rat ventricular myocytes26. Again, this disease is primarily driven by 
the excessive generation of ROS. Administration of CAT-SKL showed both increased 
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catalase content and activity in myocytes, proving its successful internalization, as 
well as a reduction in cell death in response to IRI26. Finally, according to a previous 
study by Young et. al., inflammatory skin diseases, including psoriasis, are 
exacerbated by the increased expression of inflammatory cytokines30. With addition 
of CAT-SKL, they demonstrated a significant decrease in inflammatory cytokines 
including TNF-α30. Taken together, these studies unequivocally demonstrate the 
widespread efficacy of CAT-SKL as a powerful antioxidant enzyme.  
Despite numerous studies on the efficacy of CAT-SKL in combating diseases 
mediated by the excessive generation of ROS, its efficacy against cisplatin-induced cell 
death, specifically in ameliorating its ototoxic effects, has not been defined. Previous 
studies have been conducted exploring usage of other compounds in reducing cisplatin-
induced ototoxicity, but have received mixed results. Because the majority of cisplatin 
enters hair cells through mammalian copper transporter 1 (CTR1), it was believed that 
competitively inhibiting this transporter with copper sulfate would reduce the ototoxic 
effects8. Ding et. al. did confirm the protective effects of copper sulfate in attenuating 
cisplatin-induced hair cell loss in an organotypic culture8. However, their study also 
showed at higher levels of copper sulfate, the protective agent itself was also able to 
induce cytotoxicity. Research conducted by Han et. al. also explored the usage of 
laminarin, superoxide and hydroxyl radical scavenger widely used in traditional Chinese 
medicine, in reducing cisplatin-induced ototoxicity in the HEI-OC1 cell line31. Their study 
did demonstrate that administration of laminarin was able to inhibit the mitochondrial 
apoptotic pathway through a reduction of Bax mRNA and an elevation of Bcl-2 mRNA, 
which indicated protection31. However, despite its protective effects, high doses appear 
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to cause cytotoxic effects instead of the beneficial effects31. Thus, the development of a 
safe and effective protective agent against cisplatin-induced ototoxicity is of utmost 
importance.  
Our study confirmed the successful internalization of CAT-SKL in HEI-OC1 cells 
using immunocytochemistry and western blotting (Fig. 1). In addition, results from our 
WST-1 cell viability assay showed that the administration at higher concentrations of 
CAT-SKL significantly improves their cell viability to 130% compared to untreated cells 
(Fig. 2). Also using a WST-1 assay, a similar increase in cell viability of over 100% was 
observed by Choung et. al. Their study focused on using Korean Red Ginseng (KRG) to 
prevent gentamicin-induced hearing loss in rats32. Like cisplatin, gentamicin-induced 
ototoxicity is also dependent on excessive generation of ROS32. KRG is a known 
inhibitor of ROS generation, and upon administration, reduced gentamicin-induced cell 
death32. It was demonstrated that administration of KRG, was able to induce a 
significant increase in cell viability compared to control groups – approximately 140% at 
200pg/mL32.  
Previous studies have demonstrated successful reduction of ROS formation in 
the HEI-OC1 cell line through the usage of antioxidants. Dong et. al. indicated sodium 
hydrosulfide, NaHS, is able to exert antioxidant effects due to its role as an oxygen 
scavenger33. They used the HEI-OC1 cell line and the cells were challenged with 
gentamicin, an aminoglycoside antibiotic, known to induce oxidative stress and 
apoptosis32,33. DCFH-DA fluorescence was used to confirm the increase in ROS 
production upon gentamicin administration33. NaHS pretreated groups had a noticeable 
reduction in fluorescence33. Furthermore, cells pretreated with NaHS then challenged 
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with gentamicin also exhibited greater cell viability as detected by the MTT assay, a cell 
viability assay similar to the WST-1 cell viability assay33. Similarly, we observed an 
increase in ROS production, using DHE staining, in HEI-OC1 cells challenged with 
cisplatin (Fig. 5). This increase in red fluorescence was then attenuated upon 
pretreatment with CAT-SKL, our antioxidant. We also observed a significant increase in 
cell viability in HEI-OC1 cells pretreated with CAT-SKL then challenged with cisplatin at 
all 3 concentrations (15µM, 20µM, and 30µM) when compared to cisplatin only cells 
(Fig. 4). This data suggests we are able to successfully induce oxidative stress in the 
HEI-OC1 cell line and subsequently rescue the cells from ROS stress upon 
administration of an antioxidant.  
As a marker of cell condition, we performed immunocytochemistry on HEI-OC1 
cells using anti-PMP70 (70kDa Peroxisomal Membrane Protein) antibody, a common 
marker of peroxisomes (Fig. 6). Previous studies have reported the unique ability of 
peroxisomes to proliferate and multiply in response to nutritional and extracellular 
environmental stimuli24,28. This proliferation is typically characterized by the increase in 
the number and size of peroxisomes, and an induction of peroxisomal enzymes28. 
Furthermore, it has been observed that mitochondrial abnormalities were accompanied 
by the proliferation of peroxisomes28. Studies by Feher et. al. observed noticeable 
peroxisomal proliferation in patients experiencing age-related macular degeneration in 
the cells of the retinal epithelium34. It is believed this peroxisomal proliferation occurs to 
compensate for reduced peroxisome function and to further assist the mitochondria in 
metabolizing the pathological levels of ROS25,34. As predicted, when HEI-OC1 cells 
were treated with 15uM and 30uM of cisplatin, we observed a proliferation of 
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peroxisomes in both the cell bodies and cell processes. Furthermore, when cells were 
pretreated with CAT-SKL then challenged with cisplatin, this proliferation was noticeably 
attenuated in both groups.  
Limitations of the Study and Future Directions  
The HEI-OC1 cell line is a well-established cell line, widely used in the testing of 
ototoxic compounds27,31,33. However, a limitation of this study is the translational 
potential to a mouse model. Currently, we have established the IC50 of cisplatin and 
demonstrated successful protection with CAT-SKL pretreatment, but in the future, the 
physiological concentration of cisplatin must be established in order to determine the 
protective capabilities of CAT-SKL at those concentrations. Furthermore, the 
metabolism, absorption, and toxicity of CAT-SKL on other organ systems in an in vivo 
mouse model need to be evaluated in order to confirm its safety.  
Moreover, we have yet to determine a dose response curve for the timing of 
CAT-SKL administration. Though we know CAT-SKL is internalized in HEI-OC1 cells at 
24 hours, we do not know its protective capabilities if it is co-administered with cisplatin. 
Our study has successfully demonstrated the protective abilities of CAT-SKL on 
cisplatin-induced ototoxicity. Therefore, we plan to further explore its protective effects 
on reducing ototoxicity induced by other compounds such as gentamicin, an 
aminoglycoside antibiotic. Although CAT-SKL is able to protect against cisplatin-induced 
ototoxicity, its potential interference with the therapeutic effects of cisplatin have yet to 
be verified. Another future step would be to elucidate the activity and expression of key 
proteins in the mitochondrial apoptotic pathway to evaluate the extent of protection 
conferred by CAT-SKL. Furthermore, although CAT-SKL internalization in a cell line has 
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proven to be successful, the presence of a non-discriminatory cell penetrating peptide 
may become a barrier when administering CAT-SKL into a mouse. Therefore, our lab is 
investigating the efficacy of removing the cell penetrating peptide from the CAT-SKL 
enzyme and instead using exosome encapsulation of the enzyme to allow for delivery. 
Exosomes are not only highly resistant to degradation in the blood stream, but studies 
have shown viruses can be used to modify exosomes in order to target them to very 
specific locations in the body35,36.  
Conclusion  
There currently exists a great need to develop a safe and effective protective 
agent against cisplatin-induced ototoxicity. The results of this project have proved to 
yield promising steps towards that goal. Our study has shown that CAT-SKL is not only 
harmless to HEI-OC1 cells, but at high concentrations, actually improves overall cell 
viability. Moreover, we demonstrated that cisplatin administration results in decreased 
cell viability, increased ROS formation, and induced peroxisomal proliferation – all of 
which was attenuated with CAT-SKL pretreatment. At present, there is no widely 
accepted pharmacotherapy which protects against ototoxic pharmaceuticals. Therefore, 
with the results of this project, we will be one step closer to developing a safe and 
effective prophylactic pharmaceutical therapy for protecting against ototoxic drug-
induced hearing loss. 
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